A phase II APT (adjuvant paclitaxel and trastuzumab) trial assessed the benefit of adjuvant trastuzumab plus weekly paclitaxel in 406 women with T1N0 or T2N0 HER2-positive tumors measuring up to 3 cm with predominantly stage I breast cancer. The gene discussed is ERBB2; the disease is breast cancer.